2016
SAT-163 C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
Dore G, Altice F, Litwin A, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Conway B, Gendrano I, Huang H, Chen E, Nguyen B, Wahl J, Barr E, Robertson M, Platt H. SAT-163 C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT). Journal Of Hepatology 2016, 64: s771. DOI: 10.1016/s0168-8278(16)01503-8.Peer-Reviewed Original Research
1995
Zygomycosis (Mucormycosis) and HIV Infection: Report of Three Cases and Review
Nagy-Agren S, Chu P, Smith G, Waskin H, Altice F. Zygomycosis (Mucormycosis) and HIV Infection: Report of Three Cases and Review. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 10: 441-449. PMID: 7583440, DOI: 10.1097/00042560-199512000-00007.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAIDS patientsBasal gangliaAdvanced HIV diseaseSite of involvementCases of zygomycosisInjection drug usersSite of diseaseIntravenous amphotericinLow CD4Renal zygomycosisFulminant courseHIV diseaseLymphocyte countSurgical debridementHIV infectionOverall mortalityOpportunistic infectionsImmunodeficiency virusCase reportRisk factorsRespiratory tractSuccessful therapyZygomycosisTransient episodes